Get the Stockscreener App
6.12
2.00%
0.11
Candel Therapeutics Inc stock is traded at $6.12, with a volume of 199.79K.
It is up +2.00% in the last 24 hours and up +2.00% over the past month.
Candel Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing viral immunotherapies to help patients fight cancer. The company has established two clinical-stage viral immunotherapy platforms based on novel, genetically modified adenovirus and herpes simplex virus (HSV) constructs, respectively.
See More
Previous Close:
$6.01
Open:
$6.03
24h Volume:
199.79K
Relative Volume:
0.26
Market Cap:
$336.53M
Revenue:
$124.00K
Net Income/Loss:
$-49.99M
P/E Ratio:
-3.6213
EPS:
-1.69
Net Cash Flow:
$-31.03M
1W Performance:
+3.55%
1M Performance:
+2.00%
6M Performance:
-12.68%
1Y Performance:
-5.40%
1-Day Range:
$5.98
$6.1301
1-Week Range:
$5.91
$6.62
52-Week Range:
$4.25
$13.68
Candel Therapeutics Inc Stock (CADL) Company Profile
Name
Candel Therapeutics Inc
Sector
Industry
Phone
617-916-5445
Address
117 KENDRICK STREET, NEEDHAM
Compare CADL with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CADL
Candel Therapeutics Inc
|
6.13 | 329.94M | 124.00K | -49.99M | -31.03M | -1.69 |
|
VRTX
Vertex Pharmaceuticals Inc
|
473.10 | 120.98B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
768.45 | 80.15B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
865.92 | 51.56B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
359.09 | 47.74B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
336.12 | 37.38B | 4.98B | 69.59M | 525.67M | 0.5197 |
Candel Therapeutics Inc Stock (CADL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-28-25 | Initiated | Stephens | Overweight |
| Sep-03-25 | Downgrade | BofA Securities | Buy → Neutral |
| Jun-30-25 | Resumed | H.C. Wainwright | Buy |
| Feb-20-25 | Initiated | Citigroup | Buy |
| Feb-19-25 | Initiated | Canaccord Genuity | Buy |
| Feb-07-25 | Initiated | BofA Securities | Buy |
| Dec-02-22 | Initiated | H.C. Wainwright | Buy |
| Nov-19-21 | Initiated | BMO Capital Markets | Outperform |
| Aug-23-21 | Initiated | Credit Suisse | Outperform |
| Aug-23-21 | Initiated | Jefferies | Buy |
| Aug-23-21 | Initiated | UBS | Buy |
View All
Candel Therapeutics Inc Stock (CADL) Latest News
What is the earnings history of Candel Therapeutics Inc.Insider Selling & Precise Trade Entry Recommendations - mfd.ru
Oncolytic Virotherapy Market - GlobeNewswire Inc.
Candel Therapeutics (NASDAQ:CADL) Stock Rating Lowered by Zacks Research - MarketBeat
New Strong Sell Stocks for January 20th - sharewise.com
Is Candel Therapeutics Inc. stock affected by interest rate hikesQuarterly Growth Report & Growth Focused Investment Plans - bollywoodhelpline.com
Trading the Move, Not the Narrative: (CADL) Edition - Stock Traders Daily
Breakeven On The Horizon For Candel Therapeutics, Inc. (NASDAQ:CADL) - simplywall.st
Aug Highlights: Will Xometry Inc stock recover after earningsPortfolio Risk Report & Pattern Based Trade Signal System - baoquankhu1.vn
Loss-Making Candel Therapeutics, Inc. (NASDAQ:CADL) Expected To Breakeven In The Medium-Term - Yahoo Finance
Sectors Review: Will Candel Therapeutics Inc stock maintain momentum in 2025Earnings Trend Report & Consistent Profit Alerts - Bộ Nội Vụ
Valuation Update: Will Candel Therapeutics Inc. stock outperform tech sector in 2025IPO Watch & Consistent Profit Trade Alerts - Улправда
Can Candel Therapeutics Inc. stock attract ESG capital inflows2025 Momentum Check & Consistent Return Strategy Ideas - ulpravda.ru
Aug Volume: Will Candel Therapeutics Inc. stock outperform tech sector in 20252025 Analyst Calls & Free Weekly Chart Analysis and Trade Guides - Улправда
Can Candel Therapeutics Inc. stock sustain free cash flow growth2025 Valuation Update & Trade Opportunity Analysis - Улправда
Will Candel Therapeutics Inc. stock outperform tech sector in 2025IPO Watch & Consistent Profit Trade Alerts - Улправда
Analysts Offer Insights on Healthcare Companies: Candel Therapeutics (CADL) and Stereotaxis (STXS) - The Globe and Mail
(CADL) Volatility Zones as Tactical Triggers - Stock Traders Daily
Candel Therapeutics, Inc. (NASDAQ:CADL) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat
Understanding the Setup: (CADL) and Scalable Risk - Stock Traders Daily
Candel Therapeutics, Inc.(NasdaqGM: CADL) added to NASDAQ Biotechnology Index - marketscreener.com
Can Candel Therapeutics Inc. stock surprise with earnings upside2025 Momentum Check & Risk Adjusted Buy/Sell Alerts - Улправда
Candel Therapeutics Earnings Notes - Trefis
Why Candel Therapeutics Inc. stock is rated strong buyOil Prices & Stepwise Swing Trade Plans - Улправда
Will Candel Therapeutics Inc. stock outperform Dow Jones index2025 AllTime Highs & Long-Term Capital Growth Ideas - DonanımHaber
Will Candel Therapeutics Inc. stock maintain growth storyStop Loss & AI Powered Buy and Sell Recommendations - Улправда
Bear Alert: Why Candel Therapeutics Inc. stock is rated strong buyWeekly Gains Summary & Weekly Breakout Watchlists - Улправда
How (CADL) Movements Inform Risk Allocation Models - Stock Traders Daily
B of A Securities Downgrades Candel Therapeutics (CADL) - MSN
Candel Therapeutics, Inc. $CADL is Acorn Capital Advisors LLC's 5th Largest Position - MarketBeat
Is Candel Therapeutics On The Move With Pipeline Progress And Market Momentum? - RTTNews
Diamond Hill Investment Group, Rhythm Pharmaceuticals, Vail Resorts And Other Big Stocks Moving Higher On Thursday - Benzinga
Brookline Capital Management Weighs in on CADL Q4 Earnings - MarketBeat
Citi Maintains Candel Therapeutics(CADL.US) With Buy Rating, Maintains Target Price $24 - 富途牛牛
Candel Therapeutics (NASDAQ:CADL) Shares Little Changed on Clinical-Stage Progress - Kalkine Media
Stephens Reaffirms Overweight Rating for Candel Therapeutics (NASDAQ:CADL) - MarketBeat
Candel Therapeutics, Inc. (NASDAQ:CADL) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
Candel Therapeutics (CADL) Maintains "Overweight" Rating by Step - GuruFocus
CADL: CAN-2409's phase 3 success and strong market outlook drive launch readiness and pipeline expansion - TradingView
CADL: CAN-2409's phase III success and strong market readiness position it for rapid adoption and growth - TradingView — Track All Markets
CADL: Late-stage immunotherapy programs advance toward commercialization and regulatory milestones - TradingView — Track All Markets
Candel Therapeutics, Inc. Hosts R&D Day Highlighting Viral Immunotherapy Advances - TradingView — Track All Markets
Candel Therapeutics, Inc. (CADL) Stock Analysis: Unveiling a 271% Potential Upside in Biotech - directorstalkinterviews.com
How Candel Therapeutics Inc. stock trades before earningsJuly 2025 Sentiment & AI Driven Stock Price Forecasts - Newser
Is Candel Therapeutics Inc. stock recession proof2025 Price Targets & Long-Term Capital Growth Strategies - Newser
Candel Therapeutics (CADL) Stock Analysis Report | Financials & Insights - Benzinga
Is Candel Therapeutics Inc. stock attractive after correctionWeekly Volume Report & AI Forecast for Swing Trade Picks - Newser
Is Candel Therapeutics Inc. stock resilient to inflationPortfolio Update Summary & Safe Capital Investment Plans - Newser
Candel: lighting the path to a brighter future for patients with solid tumors - Nature
Candel Therapeutics (CADL) Upgraded to Strong Buy: Here's What You Should Know - MSN
Candel Therapeutics Stock Headed For 20% Weekly Gains: Retail Over The Moon With BofA's 'Buy' Call - MSN
Candel Therapeutics stock price target raised to $14 by Freedom Capital - Investing.com Nigeria
Candel Therapeutics Inc Stock (CADL) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.26%
0.66%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):